{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:03Z","timestamp":1787698443544,"version":"build-2784847793"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen radioligand therapy (PSMA RLT) improves survival in metastatic castration-resistant prostate cancer (mCRPC). However, evidence in Japanese cohorts is limited. We evaluated the safety and efficacy of PSMA RLT in Japanese patients with mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 82 Japanese patients with mCRPC treated with PSMA RLT between 2018 and 2024 in Australia. PSMA RLT included Lutetium-177, Actinium-225, or Terbium-161 conjugated PSMA ligands, following PSMA Positron Emission Tomography \/ Computed Tomography confirmation of target expression. Endpoints were prostate-specific antigen (PSA) response (\u226550% decline), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TrAEs). Cox proportional hazards regression identified prognostic factors for survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one patients (38%) achieved a PSA response. Median PFS and OS were 4 and 20\u00a0months, respectively. While no significant difference was observed in &amp;gt;50% PSA decline, &amp;gt;80% decline was significantly higher in chemo-na\u00efve patients (43% vs. 7.4%, P\u00a0&amp;lt;\u00a0.001), with longer PFS (8 vs. 3\u00a0months, P\u00a0=\u00a0.006) and OS (not reached vs. 11\u00a0months, P\u00a0&amp;lt;\u00a0.001). On multivariable analysis, poorer performance status and prior chemotherapy were independent factors for worse OS. TrAEs of any grade occurred in 49 patients (60%), most commonly fatigue. Grade\u00a0\u2265\u00a03 TrAEs occurred in 15%, with no treatment-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PSMA RLT provided meaningful clinical benefit with favorable tolerability in Japanese patients with mCRPC, especially those without prior chemotherapy. Early integration of PSMA RLT may offer additional therapeutic advantages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf179","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:20:28Z","timestamp":1762651228000},"page":"226-233","source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of prostate-specific membrane antigen-targeted radioligand therapy in Japanese patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1124-2322","authenticated-orcid":false,"given":"Yuki","family":"Enei","sequence":"first","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-19-18 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-0712","authenticated-orcid":false,"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-19-18 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Kuruma","sequence":"additional","affiliation":[{"name":"Bashamichi Sakura Clinic , 2F, Koken Capital Building, 6-73 Ota-cho, Naka-ku, Yokohama City, Kanagawa 231-0011 ,","place":["Japan"]},{"name":"Theranostics Yokohama , 2F, Koken Capital Building, 6-73 Ota-cho, Naka-ku, Yokohama City, Kanagawa 231-0011 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Theranostics Yokohama , 2F, Koken Capital Building, 6-73 Ota-cho, Naka-ku, Yokohama City, Kanagawa 231-0011 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Jikei University School of Medicine , 3-19-18 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Okada","sequence":"additional","affiliation":[{"name":"Jinsenkai MI Clinic , 1-12-13 Shoji, Toyonaka City, Osaka 560-0004 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat","family":"Lenzo","sequence":"additional","affiliation":[{"name":"ICON Cancer Centre Theranostics , PO Box 3787, South Brisbane QLD, Perth, WA 4101 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-19-18 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-19-18 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Bashamichi Sakura Clinic , 2F, Koken Capital Building, 6-73 Ota-cho, Naka-ku, Yokohama City, Kanagawa 231-0011 ,","place":["Japan"]},{"name":"Theranostics Yokohama , 2F, Koken Capital Building, 6-73 Ota-cho, Naka-ku, Yokohama City, Kanagawa 231-0011 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2026021308522405900_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41391-019-0156-z","article-title":"Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis","volume":"23","author":"Kimura","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026021308522405900_ref2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2026021308522405900_ref3","doi-asserted-by":"publisher","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2026021308522405900_ref4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021308522405900_ref5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026021308522405900_ref6","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026021308522405900_ref7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [177Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis","volume":"65","author":"Ells","year":"2024","journal-title":"J Nucl Med"},{"key":"2026021308522405900_ref8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"2026021308522405900_ref9","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026021308522405900_ref10","doi-asserted-by":"publisher","first-page":"17588359231182292","DOI":"10.1177\/17588359231182293","article-title":"The current status of prostate cancer treatment and PSMA theranostics","volume":"15","author":"Uemura","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2026021308522405900_ref11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-021-00801-w","article-title":"Real-world data analysis of efficacy and survival after lutetium-177 labelled PSMA ligand therapy in metastatic castration-resistant prostate cancer","volume":"16","author":"Meyrick","year":"2021","journal-title":"Target Oncol"},{"key":"2026021308522405900_ref12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026021308522405900_ref13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s13246-024-01516-8","article-title":"Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET\/CT","volume":"48","author":"Molin","year":"2025","journal-title":"Phys Eng Sci Med"},{"key":"2026021308522405900_ref14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"2026021308522405900_ref15","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.3390\/cancers15204907","article-title":"Prognostic value of the DE Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy","volume":"15","author":"Gaal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026021308522405900_ref16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1055\/a-2365-8113","article-title":"Prognostic significance of baseline clinical and [68Ga]Ga-PSMA PET derived parameters on biochemical response, overall survival, and PSA progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients undergoing [177Lu]Lu-PSMA therapy","volume":"63","author":"Jafari","year":"2024","journal-title":"Nuklearmedizin"},{"key":"2026021308522405900_ref17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026021308522405900_ref18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2967\/jnumed.118.216820","article-title":"Clinical outcomes of 177Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy na\u00efve patients with metastatic castration resistant prostate cancer","volume":"60","author":"Barber","year":"2019","journal-title":"J Nucl Med"},{"key":"2026021308522405900_ref19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2967\/jnumed.122.265259","article-title":"Safety and efficacy of [177Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer: report on 80 patients over the age of 80 years","volume":"64","author":"Tauber","year":"2023","journal-title":"J Nucl Med"},{"key":"2026021308522405900_ref20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bju.16106","article-title":"Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis","volume":"132","author":"Yanagisawa","year":"2023","journal-title":"BJU Int"},{"key":"2026021308522405900_ref21","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"2026021308522405900_ref22","doi-asserted-by":"publisher","first-page":"e35843","DOI":"10.1097\/MD.0000000000035843","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617","volume":"102","author":"\u015eahin","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2026021308522405900_ref23","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026021308522405900_ref24","doi-asserted-by":"publisher","first-page":"17673","DOI":"10.1038\/s41598-023-45106-2","article-title":"Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study","volume":"13","author":"Kendrick","year":"2023","journal-title":"Sci Rep"},{"key":"2026021308522405900_ref25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-022-05927-1","article-title":"Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [68Ga]Ga-PSMA-11 PET\/CT images","volume":"50","author":"Kendrick","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026021308522405900_ref26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.21873\/anticanres.15682","article-title":"Low body weight as a risk factor for apalutamide-related cutaneous adverse events","volume":"42","author":"Katsuta","year":"2022","journal-title":"Anticancer Res"},{"key":"2026021308522405900_ref27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/jcpt.12239","article-title":"The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients\u2014case reports and literature reviews","volume":"40","author":"Lee","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"2026021308522405900_ref28","doi-asserted-by":"publisher","first-page":"e22661","DOI":"10.1371\/journal.pone.0022661","article-title":"Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients","volume":"6","author":"Nishijima","year":"2011","journal-title":"PLoS ONE"},{"key":"2026021308522405900_ref29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","article-title":"Safety analyses of the phase 3 VISION trial of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"85","author":"Chi","year":"2024","journal-title":"Eur Urol"},{"key":"2026021308522405900_ref30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/MNM.0000000000001179","article-title":"Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer\u2014a prospective pilot study in an Asian population","volume":"41","author":"Thang","year":"2020","journal-title":"Nucl Med Commun"},{"key":"2026021308522405900_ref31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.120.246983","article-title":"The Effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: A prospective, randomized, double-blind, placebo-controlled intraindividual imaging study","volume":"62","author":"Harsini","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyaf179\/65224977\/hyaf179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyaf179\/65224977\/hyaf179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:52:31Z","timestamp":1770990751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/2\/226\/8315081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,5]]},"published-print":{"date-parts":[[2026,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf179","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,5]]}}}